A
Axel Wein
Researcher at University of Erlangen-Nuremberg
Publications - 72
Citations - 1251
Axel Wein is an academic researcher from University of Erlangen-Nuremberg. The author has contributed to research in topics: Colorectal cancer & Oxaliplatin. The author has an hindex of 19, co-authored 72 publications receiving 1181 citations.
Papers
More filters
Journal ArticleDOI
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.
Markus Moehler,A Eimermacher,Jürgen Siebler,Thomas Höhler,Axel Wein,M Menges,D Flieger,Theodor Junginger,T Geer,E Gracien,Peter R. Galle,Michael Heike +11 more
TL;DR: ILF provides a better response rate than ELF, and that ILF should be investigated further for the treatment of metastatic gastric cancer, the data from this randomised phase II study indicate.
Journal ArticleDOI
NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Christoph Schulz,Frank Kullmann,Volker Kunzmann,Martin Fuchs,Michael Geissler,Ursula Vehling-Kaiser,Heribert Stauder,Axel Wein,Salah-Eddin Al-Batran,Thomas Kubin,Claus Schäfer,Sebastian Stintzing,Clemens Giessen,Dominik Paul Modest,Karsten Ridwelski,Volker Heinemann +15 more
TL;DR: This study indicates that intensified NACT with 6 cycles of FLOT is highly effective and tolerable in resectable GEC.
Journal ArticleDOI
Neoadjuvant Treatment with Weekly High-Dose 5-Fluorouracil as 24-Hour Infusion, Folinic Acid and Oxaliplatin in Patients with Primary Resectable Liver Metastases of Colorectal Cancer
Axel Wein,C. Riedel,W Brückl,Susanne Merkel,R. Ott,B. Hanke,U. Baum,F. Fuchs,K. Günther,T. Reck,T. Papadopoulos,E.G. Hahn,Werner Hohenberger +12 more
TL;DR: The neoadjuvant treatment with weekly high-dose 5-FU in the form of a 24-hour infusion combined with FA and L-OHP is very effective and well tolerated and Surgical morbidity does not appear to be increased by the neoadJuvant treatment.
Journal ArticleDOI
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer
Stefan Boeck,T. Hoehler,G. Seipelt,R. Mahlberg,Axel Wein,Andreas Hochhaus,H.-P. Boeck,B. Schmid,E. Kettner,Martina Stauch,Florian Lordick,Y. Ko,M. Geissler,K. Schoppmeyer,Georgi Kojouharoff,A. Golf,Sophie Neugebauer,Volker Heinemann +17 more
TL;DR: CapOx, CapGem and mGemOx have similar clinical efficacy in advanced PC and each regimen has a distinct but manageable tolerability profile.
Journal ArticleDOI
Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid
Axel Wein,C. Riedel,F. Köckerling,Peter Martus,Ulrich Baum,Wolfgang M. Brueckl,T. Reck,R. Ott,J. Hänsler,Thomas Bernatik,D. Becker,T. Schneider,Werner Hohenberger,Eckhart G. Hahn +13 more
TL;DR: It is shown prospectively that, after downstaging by palliative treatment using a weekly 24-h infusion of high-dose 5-FU and folinic acid, secondary curative metastatic resection was technically feasible in 11% of the patients and long-term survival is therefore possible.